These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18436256)

  • 1. Re: Obesity and prostate cancer: importance of race and stage of disease. S. J. Freedland. J Urol 2007; 178: 1842-1843.
    Bennett JK; Foote J; Alphonse P; Hood N
    J Urol; 2008 Jun; 179(6):2481-2; author reply 2482. PubMed ID: 18436256
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 3. Obesity and prostate cancer: importance of race and stage of disease.
    Freedland SJ
    J Urol; 2007 Nov; 178(5):1842-3. PubMed ID: 17868740
    [No Abstract]   [Full Text] [Related]  

  • 4. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Polascik J Urol 2018; 200: 758-766.
    Wang CS; Jhan JH; Li CC
    J Urol; 2019 Mar; 201(3):627-628. PubMed ID: 30759714
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor: B. I. Rini, L. Fong, v. Weinberg, B. Kavanaugh and E. J. Small. J Urol 2006; 175: 2087-2091.
    Brú A
    J Urol; 2007 Apr; 177(4):1585; author reply 1585-6. PubMed ID: 17382784
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tumours of kidneys, urinary bladder and prostate in obesity and diabetes].
    Svacina S
    Vnitr Lek; 2008 May; 54(5):464-7. PubMed ID: 18630627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies: R. Abouassaly, N. Tan, A. Moussa and J. S. Jones J Urol 2008; 180: 911-914.
    Feldstein MS; Hentz JG
    J Urol; 2009 Apr; 181(4):1960-1; author reply 1961. PubMed ID: 19251278
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Prostate cancer severity among low income, uninsured men. D. C. Miller, M. S. Litwin, J. Bergman, S. Stepanian, S. E. Connor, L. Kwan and W. J. Aronson. J Urol 2009; 181: 579-584.
    Watson RA
    J Urol; 2010 Mar; 183(3):1259-60; author reply 1260. PubMed ID: 20097378
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J. S. Jones, A. Patel, L. Schoenfield, J. C. Rabets, C. D. Zippe and C. Magi-Galluzzi. J Urol, 175: 485-488, 2006.
    Inman BA; Myers RP
    J Urol; 2006 Sep; 176(3):1252-3; author reply 1253. PubMed ID: 16890738
    [No Abstract]   [Full Text] [Related]  

  • 11. Obesity and prostate cancer: a growing problem.
    Freedland SJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6763-6. PubMed ID: 16203761
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. K. Eichler, S. Hempel, J. Wilby, L. Myers, L. M. Bachmann and J. Kleijnen, J Urol, 175: 1605-1612, 2006.
    Eskicorapci SY; Tuncay L
    J Urol; 2006 Dec; 176(6 Pt 1):2745; author reply 2745-6. PubMed ID: 17085209
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
    Schellhammer PF
    J Urol; 2010 Mar; 183(3):1258-9; author reply 1259. PubMed ID: 20097380
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program J. J. Tosoian, S. Loeb, A. Kettermann, P. Landis, D. J. Elliot, J. I. Epstein, A. W. Partin, H. B. Carter and L. J. Sokoll J Urol 2010; 183: 534-538.
    Papatsoris A; Bourdoumis A; Chrisofos M
    J Urol; 2010 Jul; 184(1):396-7. PubMed ID: 20488485
    [No Abstract]   [Full Text] [Related]  

  • 15. Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot?
    Agarwal N; Fletcher D; Ward J
    Clin Cancer Res; 2007 Jul; 13(13):4027. PubMed ID: 17606739
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to the article by J.E. Montie, Screen detected, low volume prostate cancer: the case for active treatment. Urol Oncol 2008;26:511-515.
    Klotz L
    Urol Oncol; 2009; 27(4):454; author reply 454. PubMed ID: 19573778
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: A multi-institutional evaluation of active surveillance for low risk prostate cancer. S. E. Eggener, A. Mueller, R. K. Berglund, R. Ayyathurai, C. Soloway, M. S. Soloway, R. Abouassaly, E. A. Klein, S. J. Jones, C. Zappavigna, L. Goldenberg, P. T. Scardino, J. A. Eastham and B. Guillonneau J Urol 2009; 181: 1635-1641.
    Ayres BE; Bott SR; Barber NJ; Langley SE; Montgomery BS
    J Urol; 2010 Sep; 184(3):1223-4; author reply 1224. PubMed ID: 20655069
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity, androgens, estrogens, and cancer risk.
    Kirschner MA; Schneider G; Ertel NH; Worton E
    Cancer Res; 1982 Aug; 42(8 Suppl):3281s-3285s. PubMed ID: 7083187
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.